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ABSTRACT
A novel corona virus named as 2019 n-CoV was identified to be the actual cause of an outbreak
of respiratory illness in Wuhan, China beginning in late December 2019. This respiratory disease
was named as COVID-19 by WHO. There are many countries affected by COVID-19 including
Pakistan. In this review we have provided a brief introduction of COVID-19 and discussed
epidemiological and phylogenetic analysis of Pakistani novel corona virus strain. Our
epidemiological analysis of data till 16th May 2020 showed rapidly increasing number of new
cases, while at the same time a higher recovery rate than number of deaths in Pakistan. Moreover,
phylogenetic analysis indicated that 2019-nCoV strain of Pakistan shared 100 % bootstrap value
with various countries’ novel corona virus strains. Similarly, phylogenetic analysis was also
conducted in comparison with SARS species to confirm our results. In this review, current
knowledge of pathogenesis, diagnosis, treatment of COVID-19 and comorbidities which could be
helpful in offering novel understanding and possible therapeutic targets for fighting against the
COVID-19 infection are discussed.
Keywords: COVID-19, 2019-ncov, phylogenetic analysis, epidemiological analysis, Pakistan ncov strain.
INTRODUCTION
Coronaviruses (CoVs) are the part of
the family Coronaviridae with subfamily and
order Orthocoronavirinae and Nidovirales
(Banerjee et al., 2019). CoVs are familiar
human pathogens, with an association to mild
acute respiratory illnesses known as the
common cold (Wilson et al., 2020). CoVs
mainly cause enzootic infections in birds and
mammals but prior outbreaks of CoVs in the
last decades, including the Severe Acute
Respiratory Syndrome (SARS)-CoV in 2002
and the Middle East Respiratory Syndrome
(MERS)-CoV in 2012, have confirmed the
deadliness of CoVs when they infect humans
by crossing species barrier (Bogoch et al.,
2020). A group of patients, with a primary
diagnosis of pneumonia of ambiguous origin,

were admitted to hospitals in late December
2019. Several of the early patients visited a
wet seafood and animal market in Wuhan,
Hubei province, China (Lu et al., 2020a).
Successive virus isolations from human
patients and their molecular analysis revealed
that the disease-causing agent was a novel
coronavirus, first named as 2019-nCoV. The
WHO (World Health Organization) revealed
the outburst of a Public Health Emergency of
International Concern (PHEIC) on January
30, 2020. Another name SARS-CoV-2 was
suggested by a study group of the
International Committee on Taxonomy of
Viruses (ICTV) based on taxonomy
phylogeny, and established practice on
February 11, 2020, afterwards this disease
was renamed by WHO as COVID-19 on
February 12, 2020. This review is focused on
45
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up to date aspects of COVID-19 and
epidemiological and phylogenetic analysis of
Pakistani n-CoV strain.
ETIOLOGY
CoVs have mainly four genera
namely, αCoV (alpha coronavirus), δCoV
(Deltacoronavirus), βCoV (Betacoronavirus)
and γCoV (Gammacoronavirus). Their
evolutionary investigations indicated that
gene sources of αCoV and βCoVs were bats
and rodents while avian species were the
gene sources of many δCoV and γCoVs.
These viruses gradually crossed species
barrier and have become evident human
pathogens (Chan et al., 2020a). The first
complete genome of the novel β genus
coronavirus (later named SARS-CoV-2) was
discovered in a patient from Wuhan by taking
broncho alveolar lavage fluid as a sample on
January 3, 2020 (Wu et al., 2020b). The
experimental report declared that the virus
had 88 % sequence similarity with two batderived SARS (severe acute respiratory
syndrome) like CoVs, but recognizably
different in nature from SARS-CoV (Lu et
al., 2020b). On the support of present data, it
appears that COVID-19 might be originally
hosted by bats, and it is a possibility that it
was transmitted to humans through pangolins
(Lam et al., 2020) or various other wild
animals that were being sold at Huanan
seafood market and successive spread
occured through human to human
transmission (Zu et al., 2020).
EPIDEMIOLOGY AND PREVALENCE
On 31 December 2019, the WHO
China Country Office was informed of cases
of pneumonia with unknown etiology,
detected in Wuhan City, Hubei Province of
China. From 31 December 2019 through 3
January 2020, a total of 44 case-patients with
pneumonia of unknown etiology were

reported to WHO by the national authorities
in China. During this reported period, the
causal agent was not identified. Data from 20
January 2020 to 8 April 2020 was observed.
On 20 January 2020, 278 confirmed cased of
2019-nCoV were reported in China out of
282 total reported cases. While on 8 April
2020, 1,353,361 confirmed cases (73,639
new) with 79,235 deaths (6,695 new) were
reported globally and 83,157 confirmed (86
new) cases and 3,342 deaths (2 new) were
reported in China, (“Coronavirus disease
2019 (COVID-19) Situation Report – 79”,
2020). Data reported on 16th May, 2020 of
most affected countries is represented in the
form of graph (Figure 1A). It consists of total
confirmed cases (affected individuals),
deaths and recovered patients of different
countries from onset of the disease till May
16, 2020.
Data of COVID-19 cases in main
areas (including five provinces) of Pakistan is
depicted in the form of graph (Figure 1B). As
is shown in the graph, the highest total
confirmed cases were in Sindh, while lowest
numbers of cases were present in Azad
Jammu Kashmir (AJK). Total deaths and
total recoveries in Pakistan, are presented in
the form of graph (Figure 1C). Data till 16th
May, 2020 showed higher recovery rate than
number of deaths as presented in graph.
Numerical data of newly identified cases on
daily basis versus newly recovered patients is
presented in graphical form as shown in
graph (Figure 1D). Number of new cases was
increasing on a daily basis and was greater
than that of recovered individuals as
indicated in the graph. Data of daily new
COVID-19 cases in Pakistan is presented in
graph (Figure 1E).
R0 (Basic Reproduction Number) is
the mean amount of secondary infection that
patient may develop in an entirely susceptible
population without any intervention (Remais,
2010). Estimation of R0 of 2019-nCoV (2.046
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3.30) indicated that 2019-nCoV has high
transmissibility as compared to other CoVs.

Figure 1: (A) Graphs of COVID-19 cases of most suffered countries, (B) total cases of Pakistan till May 16,
2020, (C) total deaths versus total recoveries in Pakistan, (D) new cases versus newly recovered cases in
Pakistan, (E) new cases of COVID-19 reported in Pakistan on daily basis.

PHYLOGENETIC ANALYSIS
Spike protein analysis of 2019-nCOV from
different countries with Pakistani novel
corona virus (n-CoV) strains
Here we aimed to reveal evolutionary
position of Pakistani n-CoV strain with
respect to n-CoV strains of different
countries based on spike (S) glycoprotein
gene analysis. For phylogenetic analysis the
dataset used included (n=17) S glycoprotein
gene sequences of current epidemic from
different countries, plus (n=2) n-CoV strains
from Pakistan (Gilgit, KPK). These
sequences were retrieved from NCBI
database

(http://www.ncbi.nlm.nih.gov/genbank/).
Evolutionary examination was conducted in
MEGA 7.0 version applying ML (maximum
likelihood) method based General Time. The
tree was constructed to scale, with the branch
lengths in same units as those of evolutionary
distances used to deduce phylogenetic-tree
(Zuckerkandl and Pauling, 1965).
This analysis suggests that novel
coronavirus S protein sequences from Gilgit
and KPK share 100% bootstrap value with nCoV protein sequences from various
countries which means that COVID-19 in
Pakistan was caused by the same n-CoV
which targeted other countries (Figure 2A).
Emergence of this virus in Pakistan might be
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due to the tourists visiting, which were
already infected or by people which were
deported by corona infected countries. Thus,
these infected people spread the disease in
natives.
Phylogenetic analysis of Pakistani n-CoV
strains V/S previously known SARS species
spike (S)-gene sequence
We further broadened the analysis by
targeting the S glycoprotein gene of the CoVs
from human SARS, bat-like CoVs, animalorigin CoVs together with MERSV and the
current outbreak of n-CoV in Pakistan. These
sequences were retrieved from NCBI
(http://www.ncbi.nlm.nih.gov/genbank/)
database. Evolutionary examination was
conducted in MEGA 7.0 version applying
ML (maximum likelihood) method based
General Time. In this phylogenetic analysis,
Pakistani nCoV strains clustered in a
monophyletic clade. Our analysis indicates
that two bat SARS-like CoVs (Bat-SLRsSHC014, and Rs3367) and two β-CoVs
(BtRs-BetaCoV/YN2018C
and
BtRsBetaCoV/YN2018D) are sharing 100%
bootstrap support with Pakistani 2019-nCoV
isolates. Our analysis confirms that this is
same coronavirus strain that infected other
countries as represented in Figure 2B.
However, spread of COVID-19 is less severe
in Pakistan as compared to other countries
according to the data till 9 April. One reason
of this less prevalence could be strong
immunity of Pakistani but further research is
needed to confirm this fact.
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Figure 2 Phylogenetic analysis of Pakistani n-CoV isolates (A) Phylogenetic analysis of spike glycoprotein gene sequences of 2019-nCoV strains (17
different countries and 2 Pakistani).The solid-red circles are for n-CoV isolates from Pakistan.(B) Phylogenetic analysis of spike glycoprotein gene
sequences of 2019-nCoV strains (17 different SARS species, 2 Pakistani).The solid-red circles are for n-CoV isolates from Pakistan.
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ORGANIZATION OF GENOME

protein of 2019-nCoV does not have any kind
of amino acid substitution (Wu et al.,

2019-nCov has single stranded RNA
genome of 29891 bases encoding 9860 amino
acids. Novel corona virus genome, similar to
other βCoVs, has two UTRs (untranslated
regions) and a polyprotein encoding single
long open reading frame. The G+C content
was found to be 38 %. Hemagglutininesterase gene which is primarily present in
lineage A β-CoVs is absent in 2019-nCoV
and its genome is organized in sequence of
5′-replicase (orf/ab)- proteins of structural
nature, nucleocapsid (N)-Envelope (E)-Spike
(S)-Membrane (M)-3′. Notably, orf3b
encodes a completely new short protein.
Moreover, new orf8 probably encodes a
secreted protein with anα-helix, following
with a β-sheet(s) consisting six strands as
shown in Figure 3A.

2020a).
E protein
Among the major structural proteins,
E protein is the most mysterious and smallest.
It plays a multi-functional role in assembly,
pathogenesis and release of virus (NietoTorres et al., 2014). Deletion or inactivation
of this protein cause changes in tropism and
morphology which in turn lead to variation in
virulence of coronavirus (DeDiego et al.,
2007). The E protein of 2019-nCoV presents
a comparable amino acid constitution without
any type of substitution (Wu et al., 2020a).
N protein

Spike glycoprotein consists of two
subunits S1 and S2. The components in these
subunits are shown in Figure 3B. It was found
that S2 subunit of novel coronavirus is
largely reserved. It is 99% identical to human
SARS-CoV and two bat SARS-like CoVs
(ZC45 and SL-CoV ZXC21). Coronaviral
proteins called spike (S) binds to ACE2
(angiotensin-converting enzyme 2) receptor
and initiates successive fusion between the
host cell membrane and envelope and in turn
help in viral entry into host cell (Kirchdoerfer
et al., 2016).

Multi-purpose
N
protein
of
coronavirus has role in increasing
transcription efficiency of virus, formation of
complex with viral genome and aids M
protein interaction required for virion
assembly (Chang et al., 2006). It consists of
three recognizably different and highly
conserved domains which are linker region
(LKR) or RNA-binding domain and a (CTD)
C-terminal domain (McBride et al., 2014).
The N protein of 2019-nCoV, in contrast with
SARS-CoV, has five amino acid mutations.
Where two are present in IDR (intrinsically
dispersed region; 26 and 25 positions), and
other in LKR (217 position), NTD (103
position) and CTD (334 position).

M protein

NSPs and accessory proteins

The most abundant protein present in
virion particle is the M protein and it provides
particular shape to viral envelope (Neuman et
al., 2011). M proteins of CoVs are very much
diverse, M-M interaction is involved in
maintaining viral scaffold (Arndt et al.,
2010). In contrast to SARS-CoV the M

Besides the crucial structural
proteins, 2019-nCoV genome also contains 8
accessory proteins (3a, 7a, 9b, 3a, 8b, p6 and
orf14) and nsp 12-16, 15 nsps, nsp1-nsp10.
2019-nCoV genome does not contain longer
8b and 8a proteins in comparison with SARSCoV. Matrix, envelope, nsp13, nsp7 or

Spike glycoprotein
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accessory proteins 8b and p6 have not been
found with any amino acid substitution with

respect to CoVs as shown in Figure 3C (Wu
et al., 2020a).

Figure 3: (A) Organization of βcoronavirus. The genome is composed of ORF (open reading frame), 1ab (Steel
blue box), nsp ( non-structural proteins), structural proteins including envelope (dark khaki box), spike (Slate
gray box), membrane (chocolate box), accessory proteins (Corn flower blue box) such as orf 9b, 7b, 7a, 8, 3 and
6, similarly nucleocapsid proteins (dark slate blue box) and 5'-UTR in the 2019-n CoV. Example of lineages is
from A to D. The length of orfs and nsps are not drawn to scale. (B) Components of S1 and S2 subunits. S1
subunit has S-peptide (single peptide), RBD (receptor binding domain), NTD (N-terminal domain) while S2
subunit has F-peptide (fusion peptide), HP (heptad repeat), CM (cytoplasmic domain), TM (transmembrane
domain). (C) Structure of 2019-nCoV. “S” (spike glycoprotein), “M” (membrane protein), “N” (nucleocapsid
protein), “E” (envelope protein), “ssRNA” (single stranded positive sense RNA).

MOLECULAR
COMPARISON
BETWEEN ACE2 RECEPTORS OF
HUMAN AND ANIMAL SPECIES
The recognition of residues of contact
between human ACE2 and 2019-nCoV
receptor binding domain permit estimation of
whether 2019-nCoV is able to infect other
species. To evaluate this Sun et al., (2020)
aligned amino acid sequences of all available
ACE2 with human ACE. They focused on Nglycosylation of motifs near the binding site,
as they may affect attachment of S (Sun et al.,
2020). The molecular differences they found
are given in Table 1. Particularly, binding of
S from SARS-CoV to rat is prevented by
glycosylation of residue 82 (Li et al., 2005).
Further Sun et al., (2020) found that amino
acid differences in ACE2 affect binding of
2019-nCoV in various species. Studies of S

binding site of ACE2 from various species
disclose that ten and nine amino acid
differences are found in rodents (mouse and
rat respectively), eleven in chicken, and only
three are present in cats as compared with
ACE2 of human. ACE2 of human is identical
to ACE2 from chimpanzees and macaque.
So, these amino acid and glycosylation
differences make these animals reservoirs for
2019-n CoV. A structure model examination
shows that 2019-nCoV binds with ACE2 of
host with above 10 folds higher affinity than
SARS-CoV (Wrapp et al., 2020). These
findings explain the faster transmission
ability of 2019-n CoV in humans than SARSCoV, and this may be reason of much higher
confirmed COVID-19 cases than SARS-CoV
infection. Taking into consideration the high
affinity of 2019-nCoV binding with ACE2,
soluble ACE2 might be a possible approach
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for treatment of COVID-19 treatment.
Patients with COVID-19 exhibit similar
clinical signs and symptoms with those of
SARS-CoV and MERS-CoV infections
(Huang et al., 2020). Since pathogenesis of
COVID-19 is not properly understood by

scientist, the somewhat similar mechanism of
MERS-CoV and SARS-CoV can give us
much information about pathogenesis of
2019-nCoV infection to facilitate our
understanding about COVID-19.

Table 1: Glycosylation differences of ACE motifs in different species.
Species

Glycosylation Sites

Human

N53, N90, N322*

Mouse, pig, raccoon, fox, chicken, N.
procyonoides, ferret, E. telfairi and civet
Sheep, rat, cattle, pangolin, E. telfairi,
mouse
Additional glycosylation motif in this region of ACE2 in some species
Chicken

L79

Rat, Rhinolophus sinicus, and pangolin

M82

Sites at which glycosylation does
not occur

N90
N322

*N322 common in all species

PATHOGENESIS
CORONAVIRUS

OF

THE

Entry and replication of coronavirus
Cell receptors, ACE2, for 2019-nCoV
are found in lower respiratory tract of humans
(Jia et al., 2005). S-glycoprotein on the
surface of virion is capable of attachment to
these (ACE2) receptors (Tortorici and
Veesler, 2019). The entrance of SARS-CoV
into the cell was primarily recognized to be
accomplished by face to face fusion between
the plasma membrane and virus. Belouzard et
al. (2009) discovered that membrane fusion
and viral infectivity of SARS-CoV is
mediated by critical proteolytic cleavage
event at S2' position of ‘S- protein’. In
addition to membrane fusion clathrinindependent and dependent endocytosis
mediated entry of SARS-CoV has also been

observed (Wang et al., 2008). After the virus
entry into the cell, the viral genome is
released into the cytoplasm and is translated
into two (pp1a, pp1ab) polyproteins (de
Wilde et al., 2017), which encodes NTP (nonstructural proteins) and form RTC
(replication
transcriptional
complex)
(Sawicki and Sawicki, 2005). Newly
synthesized envelope glycoproteins, genomic
RNA and nucleocapsid proteins arrange and
from viral particle buds. At the end, viruses
are released by the fusion of these virus
containing vesicles with plasma membrane
(de Wit et al., 2016).
Antigen presentation during coronavirus
infection
The direct infection of T cells and
macrophages by SARS-CoV has been
reported, but it is still unknown whether
2019-nCoV
infects
immune
cells
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(Prompetchara et al., 2020). In the central
part of the body’s anti-viral immunity, after
the entry of virus in the cells, its antigen
would be presented to APC (antigen
presenting
cells).
MHC
(major
histocompatibility complex) or HLA (human
leukocyte antigen) in humans presents the
antigenic peptides, which are then recognized
by the CTLs (cytotoxic T lymphocytes).
Thus, comprehension of 2019-nCoV antigen
presentation will help our understanding of
COVID-19 pathogenesis.
Humoral and cellular immunity
Presentation of antigen then activates
the body’s cellular and humoral immunity,
virus-specific B and T cells are responsible
for this immunity. IgG and IgM production
occurs against SARS-CoV virus, similar to
some common acute viral infection. IgG
antibodies may principally play protective
role, as they can last for longer time, while
SARS-specific IgM antibodies vanish at the
end of week 12 (Li et al., 2003). SARSspecific IgG antibodies are mainly N-specific
and S-specific antibodies. A recent report
showed that the number of CD8+ and CD4+
T-cells was remarkably reduced in peripheral
blood of 2019-nCoV infected patients,
although its status is too much activation, as
revealed by high fraction of CD38 (CD8 39.4
%) and HLA-DR (CD4 3.47 %) doublepositive proportions (Xu et al., 2020). In the
same way in patients with SARS-CoV, the
acute phase response is related with a serious
decrease of CD8+ and CD4+ T-cells. In
SARS-CoV recovered individuals, even if
there is no antigen present, the memory Tcells will remain present for four years and
can carry out T-cell multiplication,
production of IFN-γ and DTH response (Fan

et al., 2009).The particular CD8+ T cells also
exhibit a similar effect on MERS-CoV
clearance in mice. These previous findings
may give valuable details for the rational
design of vaccines against 2019-nCoV.
COVID-19 and Cytokine storm
In case of CoVs infection (SARSCoV, 2019-nCoV and MERS-CoV) acute
respiratory distress syndrome (ARDS) is the
usual immunopathological event (Xu et al.,
2020).
The
uncontrolled
deadly
inflammatory response is produced due to
release of a very large amount of IL-16, IL18, IL-12, IL-33, IFN-γ,IL-1β, TNF-β, IFNα and TGFα, etc. (pro-inflammatory
cytokines) and CCL3, CXCL8, CXCL10,
CCL2, CCL5, CXCL9 etc. (chemokines) in
SARS-CoV infection, by immune effector
cells (Williams and Chambers, 2014). Some
plasma chemokines and cytokines were also
found to be increased in case of COVID-19
patients, these include different types of
interleukin (IL-2, IL-1, IL-10, IL-7, IL-17,
IL-13, IL-12, IL-1), G-CSF (Granulocytecolony
stimulating
factor)
M-CSF
(macrophage colony stimulating factor),
HGF (hepatocyte growth factor), MCP-1α,
MCP-1,IP-10, TNF-α and IFN-γ (Chen et al.,
2020). Accumulatively, the virus particles
occupy the respiratory mucosa at first and
then infect other cells of the body, they
initiate the synthesis of cytokine storm in the
body and a series of immune responses as
shown in Figure 4. This cytokine storm will
activate an intense attack to the body by
immune system causing multiple organ
failure and will at the end lead to the death of
severe cases of 2019-nCoV infection (Xu et
al., 2020).
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Figure 4: Pathogenesis of 2019-n-CoV; 2019-nCoV entry and replication. 1: Attachment of virus with ACE2
receptors. 2: Vesicle formation. 3: Virus entry in cell. 4: Replication of genome. 5: Newly synthesized viral
particle buds. 6: Released viral particles, Antigen Presentation MP (macrophage particles), DC (dendritic
cells), EC (epithelial cells), APC (antigen presenting cells), CK (cytokines),Cellular immunity CK (cytokines),
TC (T-cells/lymphocytes), Humoral immunity PC (plasma cells), M-BC (memory B-cells), Th2-C (helper -T
cells).

Incubation Period of 2019-nCoV

Transmission of Coronavirus

The average incubation period of 5.2
days was reported by a study of initial
transmission kinetics of 2019-nCo (Backer et
al., 2020). In a later study, performed based
on appearance of symptoms and travel
history of 88 confirmed patients, a
comparable average incubation period of 6.4
days was described. A unique case was
reported having an incubation period as long
as 19 days (Bai et al., 2020). Particularly, a
long
incubation
time
indicates
acclimatization in screening and control
policies (Jiang et al., 2020). In the recent
guidelines provided by Chinese health
authorities, a mean incubation period of 7
days, varying from 2-14 days was declared.

Two main transmissions of 2019nCoV are zoonotic (via contact with animals)
and anthroponotic (via direct or indirect
contact
with
affected
individual)
transmissions. Many wild and tame animals,
comprising cats, cattle and bats can function
as host for different coronaviruses. Snakes
and pangolins at untamed animal stores were
seemingly to be intermediary hosts of 2019nCoV, as shown by latest studies however
evidence of human to human viral
transmission has also been reported (Liu et
al., 2020). Three main, human to human
routes for transmission of COVID-19 include
direct transmission (respiratory droplets), and
indirect routes of transmission (fomites and
aerosols). Contact transmission can occur
when a person comes in contact with an
object or a surface, which is already
54
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contaminated with virus and thereafter
touches his/her nose, eyes or mouth
(transmission through fomites). Respiratory
droplets are formed when an infected
individual sneezes or coughs for distances
longer than six feet; these droplets travel in
the form of aerosols. Digestive system, as
another possible route of transmission of
2019-nCoV was described by another study
in which it was observed that ACE2 was
immensely expressed in absorptive cells of
alimentary tract from colon and ileum (Zhang
et al., 2020).

Clinical and laboratory findings
After an approximate incubation time
of 5.2 days, symptoms of 2019-nCoV viral
infection become visible (Li et al., 2020a).
Guidelines for treatment and diagnosis of
2019-nCoV (Wang et al., 2020b) are made
and updated by NHC (National Health
Center) of China, on the basis of broad range
of connected ideas of disease severity. Based
on the severity of associated symptoms,
COVID-19 is now organized into four levels:
critical, severe, moderate and mild. Their
associated clinical and laboratory features are
described in Table 2. Cases ending in death
were chiefly middle-aged and old-age
patients already having any other disease(s)
such as diabetes, PD (Parkinson disease),
CHD (Coronary Heart Disease), cirrhosis,
hypertension or tumor surgery (Li et al.,
2020b).
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Table 2: Clinical & Laboratory findings of COVID-19.
Clinical Feature

Laboratory features

Complicated dyspnea, myalgia, cough, pneumonia &
fever are frequently reported systems, while diarrhea is
uncommon.

Viral load decreased total lymphocytes, prolonged
APTTa&PTb, and increased level of creatinine, ALTc,
ASTd, blood urea, thrombocytopenia, increased cTnIe&
angiotensin II, decreased ALBf.

Mild patients: mild fatigue, no pneumonia and low
fever.

Most patients: increased ESRg, & CRPh with normal
procalcitonin.

Moderate patients: radiographic features, fever and
respiratory symptoms.

Severe cases: Elevated D-dimer, FDPi, decreased
lymphocytes in peripheral blood.

Severe patients: hypoxemia/dyspnea one week after the
onset of disease.

Patients of ICU: elevated
inflammatory cytokines.

Critical patients: ARDSk, shock, multiple organ failure.
Anorexia, dyspnea and abdominal pain were also
common.

Non-survivors: elevated blood
creatinine and neutrophil count.

TNFαj
urea,

and

other

D-dimer,

a

APTT: Activated partial thromboplastin time, b PT: Prothrombin time,cALT: Alanine transaminase, d AST: Aspartate
transaminase, e cTnI: Cardiac troponin I, f ALB: Albumin, g ESR: Erythrocyte sedimentation rate, h CRP: C-reactive
protein, i FDR: Fibrin degradation product, j TNFα: Tumor necrosis factor α, k ARDS: Acute respiratory distress
syndrome.

ADVANCEMENT IN DIAGNOSIS OF COVID-19
Immediate and precise diagnosis of COVID-19 is critical to control outset in hospitals or
in any community (To et al., 2020). Auxiliary assessments like epidemiological history,
understanding of clinical symptoms and radiographic characteristics are essential for diagnosing
2019-nCoV and associated irregular symptoms (Li et al., 2020c). Description of different
techniques is given in Table 3.
Table 3: Techniques and their description.
Techniques

Description
NGS and virus blood culture are authorized methods
but cannot be used because of high price &
equipment dependency (Zhou et al., 2020).

Nucleic acid detection methods

RT-qPCR is most ordinary, efficient and simple
technique gives 50-79% sensitivity (Yam et al.,
2003) also gives *FNR.
RT-LAMP is very precise, has sensitivity similar
with rRT-PCR & is used for detection of MERS-CoV
(Huang et al., 2018).
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From three RT-PCR assays, RdRp/helicase method
is highly reactive& and is regarded as specific and
recommended assay (Chan et al., 2020b).
Cobas 6800 with a good systematic operation takes
less time & offers authentic results (Eigner et al.,
2019).

Computerized Tomography (CT) Scans

Used in combination with rRT-PCR particularly for
early detection & evaluation of severeness of disease
(Pan et al., 2020). However, contain inadequacies
e.g. being indistinct from pneumonia caused by other
viruses & hysteresis of unusual CT imaging.

Enzyme Linked Immunosorbent Assay (ELISA)

Exhibit higher diagnostic rates than other techniques
& is highly suggested method (Wang et al., 2020a).
It has fast turnaround time & comparatively low
costs. A warning is that it can give **FPR, because
of conservative N-protein of 2019-nCoV.

*False negative result ** False positive result

ADVANCEMENT IN TREATMENT
Drugs and herbal treatment
Treatment of COVID-19 by using different drugs and herbal plants or their extracts is summarized
in Table 4.
Table 4 Different drugs and herbal plants used in treatment of COVID-19.
Drug name
Composition

&

Ciclesonide
(steroid drug)

Metronidazole
(contain
redox
operative pro-drugs)

Function

Case
studies/Findings

Represses asthmatic
spasms,
inhibits
eosinophils
percolation
into
respiratory canal, and
represses synthesis of
IL 4, 5 and TNF-α.

A study shows that
respiratory status in
patients of COVID19 can be improved
by this drug.

Reduces levels of IL8, 1B, 6, 12, TNF-α,
interferon
gamma,
neutrophil count &
ROS, CRP.

Can
serve
as
possible candidate
to prevent most of
immunopathological

Comments
(Suggestions/Side
effects)
It
contains
less
systemic side effects
& is virtuous for
additional study in
clinical trials.

References

The need is to do
clinical examination
with huge sample
size to find out its

(Bayraktar et al.,
2005)

(Nakajima et al.,
2020)

57

Altaf et al. (2020). Epidemiological and Phylogenetic Analysis of Novel Corona Virus: A Review
J Biores Manag. 7 (3): 45-65
characteristics
COVID-19.
Teicoplanin

of

efficiency to
COVID-19.

cure

Used to cure bacterial
infections, but already
efficient
against
viruses, acts on the
initial step of virus life
cycle.

Zhou et al reported
that
it
stops
liberation of viral
genomic RNA & the
protraction of virus
replication occurs.

Further
analysis
about
its
effect
against COVID-19 is
needed & it suggests
that this drug can
serve as potential
alternative to cure
COVID-19.

(Colson
&
Raoult, 2016)

Thalidomide
combined with low
dose glucocorticoid

Anti-inflammatory
inhibits
cell
proliferation,
decreases pulmonary
fibrosis and lung
injury.

Clinical condition,
absolute
lymphocyte value
and cytokine level
were improved by a
study of Chen et al.
Improved
absorption
of
pulmonary
exudation was also
obtained.

It may be used as
adjuvant treatment
strategy
for
potentially fatal viral
disease.

(Wen
2018)

et

al.,

Hydroxychloroquine
& azithromycin

Also effective in
removing
nasopharyngeal
carriage of virus in 36 days

A clinical trial
performed by P
Gautret
et
al.
showed that all
patients receiving
these drugs were
cured at the day 6 of
post inclusion

These findings need
further research to
check whether this
combination
is
effective in severe
cases

(Biot
2006)

et

al.,

Chloroquine

Prevent binding of
virus to cell surface,
may interfere at the
budding step of the
replication cycle of
virus, can disable viral
proteins
proper
maturation. Reduces
level
of
proinflammatory
cytokines

Recommended as
an effective drug
against COVID-19,
presently
ten
clinical trials are
trying to test the
effectiveness of this
drug as an antiCOVID-19 therapy

A survey study is
needed to check the
adverse effects of
therapy done by
using this drug

(Randolph et al.,
1990)

Protease inhibitors of
2019-nCoV.

In a study by
Ambrish
K.
Srivastava et al. the
inhibition capability
of their extracts was
found.

Can serve as effective
therapeutic
agents
against COVID-19
infection due to their
non-toxic nature.

(Srivastava
al., 2020)

(Glycopeptides
immunoglobulin)

(multi-purpose
bioactive agent in
vitro)

Indian herbal plants
(Giloy, aloe vera,
neem,
ginger,
turmeric,
ashwagandha etc)

et
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Traditional Chinese
Medicines

Halt the activity of
SARS
3CLpro
enzyme, also halt
helicase protein of
SARS-CoV namely,
nsP13 in laboratory by
disturbing
ATPase
activity.

Inhibition of lung
inflammation
&
reduced levels of
cytokines
along
with IL β and 6 is
obtained by the
injection of Shen
Fu, as described by
Wang, et al.

Treatment using antibodies and Vaccines
Monoclonal
antibodies
target
susceptible sites on the surface of viral
proteins, first reported monoclonal antibody
that reacted with 2019-nCoV was 47D11. In
a latest report, use of convalescent plasma
was identified as a possible treatment for
COVID-19 (Zhang et al., 2020). A metaanalysis from previous study revealed a
decrease in death rate by receiving diverse
dosage of convalescent plasma in patients
having serious respiratory infections, with no
unfavorable events or problems after
treatment (Mair-Jenkins et al., 2015). One
practicable explanation for the efficiency of
convalescent plasma therapy is that
immunoglobulins from convalescent plasma
could reduce viraemia. Hence, it can be
beneficial to test the security and
effectiveness of convalescent plasma
transfusion in COVID-19 infected patients.
Antigen S has been involved in various kinds
of vaccines against contamination by CoVs
(Yu et al., 2020). Moderna declared the
commencement of phase#1 testing of mRNA
vaccine-1273 on 16 March. On 24 February
2020, Moderna declared the release of first
batch of this vaccine for use in humans
against 2019-nCoV (Anon., 2020).
GlaxoSmithKline (GSK) declared a
co-operation with a Chinese company to
assess COVID-19 vaccine. This participation
was able to produce COVID-19 S Trimer
vaccine
with
adjuvant
system.

Convincing evidence
is
that
herbal
products of some
traditional Chinese
medicines or their
parts possess strong
immuno-suppressive
impacts.

(Chen
2002)

et

al.,

Us20060039926
(patent)
application
revealed live attenuated torovirus or
coronavirus vaccines. Interestingly, GLS5300 (INO-4700) is already under phase#1
clinical analysis. The vaccine was welltolerated, inducing immunoglobulin response
in 94% of patients after 3 injections. Its
immune reactions were not dependent on
dose and it was effective through 1 year of
follow-up (Modjarrad et al., 2019). It was
suggested by a research, that BCG vaccine
seemed to significantly decrease number of
deaths caused by COVID-19 (Miller et al.,
2020). It is necessary to synthesize safe and
efficacious vaccines to restrain COVID-19
epidemic, eradicate its spread and eventually
stop its recurrence in future.
COVID-19 AND COMORBIDITIES
Comorbidities are risk factors for
2019-nCoV infection. Diseases like CVD
(cardiovascular diseases), DB (diabetes
mellitus), HTN (hypertension), RSD
(respiratory system disease) and their
susceptibility states, might be connected to
the generation and development of COVID19. These metabolic diseases can impair the
function of macrophages and lymphocytes
making a person more vulnerable to
complication of other diseases. In a research,
among patients having serious symptoms of
COVID-19, 25%, 44% and 58% people had
heart diseases, arrhythmia and hypertension
respectively (Bai et al., 2020). In accordance
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with mortality data provided by NHC, 17%
patients with COVID-19 had history of CHD,
while 35% patients had hypertension.
Similarly, it has been reported that
patients with T2DM (type-2 diabetes
mellitus) and metabolic syndromes when
they were infected with COVID-19, had
increased chances of death by up to ten-times
(Yang et al., 2006). During the course of
SARS in 2003, multiple organ involvement
such as gastrointestinal tract, liver and kidney
was reported. Recently, quite similar multiorgan involvement has been documented in
COVID-19 patients. It has been reported that
13.1% and 14.4% patients in the study had
impaired BUN (blood urea nitrogen) and
creatinine levels (Cheng et al., 2020).
Moreover, in a recent analysis done by China
(Sidaway, 2020), 18 out of 1590 COVID-19
infected individuals had a history of cancer.
The available evidence is insufficient, but it
proposes that symptoms of COVID-19 are
very likely more critical in patients having
cancer as compared to those without. Hence,
we may assume that underlying diseases like
DB, HTN, CVD, RSD and cancer may be risk
factors for severe patients of COVID-19 in
comparison with non-severe patients.

IgG and IgM, detection of nucleic acid, blood
culturing and CT scans are methods for the
clinical diagnosis of COVID-19. Until now,
specific vaccines or anti-viral medicines
against COVID-19 do not exist for potential
cure of humans. The only alternative
available is utilization of broad spectrum
anti-viral medicines and other drugs to
reduce associated symptoms like respiratory
issues, inflammation etc. It is concluded that
COVID-19 associated symptoms and
mortality may be reduced mainly by adapting
preventive measures as up to now no specific
vaccine is available for its cure.
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